Upregulation of VEGFA at 6p21.1 in C2 could increase the malignancy of tumor cells and was often accompanied by hypoxia, angiogenesis, and immunosuppressive TME, suggesting tolerance to immunotherapy (Wang et al., 2020). This evidence concerns the gene VEGFA and neoplasm.